Article ID Journal Published Year Pages File Type
9872561 International Journal of Radiation Oncology*Biology*Physics 2005 7 Pages PDF
Abstract
Conclusion: The recommended UFT dose for Phase II studies is 200 mg/m2/d given orally in two divided doses when given with leucovorin, cisplatin, and radiotherapy.
Keywords
Related Topics
Physical Sciences and Engineering Physics and Astronomy Radiation
Preview
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancer
Authors
, , , , , , , , , , , , ,